Tesaro Inc

Tesaro — Q1 2014 Earnings Presentation

18 slides from Tesaro's earnings presentation, Apr 30, 2014

  1. Slide 1: First-Quarter Operating Results April 30, 2014

    First-Quarter Operating Results April 30, 2014

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,

  3. Slide 3: Lonnie Moulder, Chief Executive Officer

    Lonnie Moulder Chief Executive Officer

  4. Slide 4: A Balanced Portfolio of Product Candidates

    A/C: anthracycline/cyclophosphamide MEC: Moderately emetogenic chemotherapy; HEC: Highly emetogenic chemotherapy NSCLC: Non-small cell lung cancer * In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration A Balanced Portfolio of Product Candidates Compound Indication Disc

  5. Slide 5: Ted English, Vice President, Finance & Administration

    Ted English Vice President, Finance & Administration

  6. Slide 6: Q1 2014 Financial Results

    Q1 2014 Financial Results Three Months Ended March 31, 2014 Three Months Ended March 31, 2013 Expenses: Research & Development $28,117 $16,503 General & Administrative 4,688 2,400 Acquired In-process R&D 17,000 - Total Expenses 49,805 18,903 Loss from Operations (49,805) (18,903) Interest Income 5 3

  7. Slide 7: Mary Lynne Hedley, Ph.D., President

    Mary Lynne Hedley, Ph.D. President

  8. Slide 8: Development Programs Update

    HEC: Highly emetogenic chemotherapy ASCO: American Society of Clinical Oncology MASCC: Multinational Association of Supportive Care in Cancer MAD: Multiple ascending dose Development Programs Update Phase 3 BRAVO trial enrollment underway Phase 3 NOVA trial enrollment in line with expectations Defin

  9. Slide 9: Development Programs Update

    HEC: Highly emetogenic chemotherapy ASCO: American Society of Clinical Oncology MASCC: Multinational Association of Supportive Care in Cancer MAD: Multiple ascending dose Development Programs Update Phase 3 BRAVO trial enrollment underway Phase 3 NOVA trial enrollment in line with expectations Defin

  10. Slide 10: Development Programs Update

    HEC: Highly emetogenic chemotherapy ASCO: American Society of Clinical Oncology MASCC: Multinational Association of Supportive Care in Cancer MAD: Multiple ascending dose Development Programs Update Phase 3 BRAVO trial enrollment underway Phase 3 NOVA trial enrollment in line with expectations Defin

  11. Slide 11: Development Programs Update

    HEC: Highly emetogenic chemotherapy ASCO: American Society of Clinical Oncology MASCC: Multinational Association of Supportive Care in Cancer MAD: Multiple ascending dose Development Programs Update Phase 3 BRAVO trial enrollment underway Phase 3 NOVA trial enrollment in line with expectations Defin

  12. Slide 12: Lonnie Moulder, Chief Executive Officer

    Lonnie Moulder Chief Executive Officer

  13. Slide 13: TESARO at ASCO: Eight Abstracts, Six Poster Presentations

    1Publication only TMZ: temozolomide MEC: Moderately emetogenic chemotherapy HEC: Highly emetogenic chemotherapy TESARO at ASCO: Eight Abstracts, Six Poster Presentations Phase 3 data in cisplatin-treated patients (HEC) Phase 3 data in AC & carboplatin-treated patients (MEC) Safety analyses Rolapitan

  14. Slide 14: Commercial Organization: Hiring Targeted for Late in NDA Review Process

    Commercial Organization: Hiring Targeted for Late in NDA Review Process Approximately 120 Total Headcount Opportunity for Significant Leverage: Anticipate Rolapitant P&L to Break Even at Annual Sales of ~$50-60M NDA: New Drug Application Field Sales Organization Medical Science Liaisons Reimbursemen

  15. Slide 15: TESARO is Positioned for Success

    CINV: chemotherapy-induced nausea & vomiting ALKi: ALK inhibitor KOL: key opinion leader TESARO is Positioned for Success Cash and equivalents of ~$180M as of 3/31/2014 Net proceeds of ~$94M from February 2014 follow-on offering Well Capitalized Commercial, development and regulatory experience in o

  16. Slide 16: Q&A

    Q&A W TESARO

  17. Slide 17: 2014 Key Priorities

    Announce top-line rolapitant data from final Phase 3 trial Present data at ASCO, MASCC and ESMO Submit NDA for oral rolapitant to the U.S. FDA in mid-2014 Advance IV rolapitant clinical program Continue to advance niraparib Phase 3 NOVA and BRAVO trials Expand the niraparib clinical development prog

  18. Slide 18: First-Quarter Operating Results April 30, 2014

    First-Quarter Operating Results April 30, 2014

TESARO — Q1 2014 Earnings Presentation on 6ix